A Pilot Trial of PET Imaging with (89)Zr-DFO-Trastuzumab in Esophagogastric Cancer


Full Title

Pilot Trial of PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer


In this study, researchers are assessing the use of a drug called 89Zr-DFO-trastuzumab to see if it enhances the appearance of esophagogastric cancer on a positron emission tomography (PET) scan. Esophagogastric cancer is cancer of the juncture between the esophagus and the stomach. The investigators will also see how long 89Zr-DFO-trastuzumab stays in the blood when given in small amounts.

DFO is a “chelating agent” that binds radioactive metals. It is linked to trastuzumab, an antibody which binds to the HER2 protein on the cancer cells of some patients with esophagogastric cancer. Attaching the radioactive substance 89Zr to DFO-trastuzumab enables the PET scanner to visualize where the DFO-trastuzumab is binding inside a patient’s body.

The results of this study may enable doctors to use PET scanning to identify, without having to do a biopsy, which patients have esophagogastric cancers that have HER2 on the surface of their cancer cells, and to possibly measure whether treatments that target HER2 are affecting the tumor.


This study will include patients being treated at Memorial Sloan Kettering Cancer Center for HER2-positive esophagogastric cancer.

For more information about this study, please contact Dr. Yelena Janjigian at 646-888-4186.